The Oct1 transcription factor and epithelial malignancies: Old protein learns new tricks

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1859, Issue 6, 2016, Pages 792-804

  Vázquez Arreguín, Karina ^a   Tantin, Dean ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Jmjd1a KDM3A; Lung adenocarcinoma; NuRD; Oct1 POU2F1; Prostate cancer; Thyroid cancer

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 1; HISTONE; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; KDM3A PROTEIN, HUMAN; POU2F1 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; BINDING SITE; CARCINOGENESIS; CELL PROLIFERATION; CELL STRESS; CELL VIABILITY; DISEASE FREE SURVIVAL; DNA METHYLATION; EPITHELIUM TUMOR; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; METABOLIC REGULATION; MISSENSE MUTATION; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; AMINO ACID SEQUENCE; GENETICS; METABOLISM; MOLECULAR GENETICS; NEOPLASM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; BINDING SITES; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; MOLECULAR SEQUENCE DATA; NEOPLASMS, GLANDULAR AND EPITHELIAL; OCTAMER TRANSCRIPTION FACTOR-1; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84973136634     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2016.02.007     Document Type: Article

References (140)

1. [1] Gerster, T., Roeder, R.G., A herpesvirus trans-activating protein interacts with transcription factor OTF-1 and other cellular proteins. Proc. Natl. Acad. Sci. U. S. A. 85:17 (Sep. 1988), 6347–6351.
2. [2] Pruijn, G.J.M., van Driel, W., van der Vliet, P.C., Nuclear factor III, a novel sequence-specific DNA-binding protein from HeLa cells stimulating adenovirus DNA replication. Nature 322:6080 (Aug. 1986), 656–659.
3. [3] Sturm, R., Baumruker, T., Franza, B.R., Herr, W., A 100-kD HeLa cell octamer binding protein (OBP100) interacts differently with two separate octamer-related sequences within the SV40 enhancer. Genes Dev. 1:10 (Dec. 1987), 1147–1160.
4. [4] Ballard, D.W., Bothwell, A., Mutational analysis of the immunoglobulin heavy chain promoter region. Proc. Natl. Acad. Sci. U. S. A. 83:24 (Dec. 1986), 9626–9630.
5. [5] Falkner, F.G., Zachau, H.G., Correct transcription of an immunoglobulin kappa gene requires an upstream fragment containing conserved sequence elements. Nature 310:5972 (Jul. 1984), 71–74.
6. [6] Mason, J.O., Williams, G.T., Neuberger, M.S., Transcription cell type specificity is conferred by an immunoglobulin VH gene promoter that includes a functional consensus sequence. Cell 41:2 (Jun. 1985), 479–487.
7. [7] Sive, H.L., Roeder, R.G., Interaction of a common factor with conserved promoter and enhancer sequences in histone H2B, immunoglobulin, and U2 small nuclear RNA (snRNA) genes. Proc. Natl. Acad. Sci. U. S. A. 83:17 (Sep. 1986), 6382–6386.
8. [8] Tanaka, M., Grossniklaus, U., Herr, W., Hernandez, N., Activation of the U2 snRNA promoter by the octamer motif defines a new class of RNA polymerase II enhancer elements. Genes Dev. 2:12b (Dec. 1988), 1764–1778.
9. [9] Ullman, K.S., Flanagan, W.M., Edwards, C.A., Crabtree, G.R., Activation of early gene expression in T lymphocytes by Oct-1 and an inducible protein, OAP40. Science 254:5031 (Oct. 1991), 558–562.
10. [10] Hentsch, B., Mouzaki, A., Pfeuffer, I., Rungger, D., Serfling, E., The weak, fine-tuned binding of ubiquitous transcription factors to the Il-2 enhancer contributes to its T cell-restricted activity. Nucleic Acids Res. 20:11 (Jun. 1992), 2657–2665.
11. [11] Sturm, R.A., Das, G., Herr, W., The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain. Genes Dev. 2:12a (Dec. 1988), 1582–1599.
12. [12] Herr, W., Sturm, R.A., Clerc, R.G., Corcoran, L.M., Baltimore, D., Sharp, P.A., Ingraham, H.A., Rosenfeld, M.G., Finney, M., Ruvkun, G., The POU domain: a large conserved region in the mammalian pit-1, oct-1, oct-2, and Caenorhabditis elegans unc-86 gene products. Genes Dev. 2:12a (Dec. 1988), 1513–1516.
13. [13] Tantin, D., Oct transcription factors in development and stem cells: insights and mechanisms. Development 140:14 (Jul. 2013), 2857–2866.
14. [14] Jin, T., Branch, D.R., Zhang, X., Qi, S., Youngson, B., Goss, P.E., Examination of POU homeobox gene expression in human breast cancer cells. Int. J. Cancer 81:1 (Mar. 1999), 104–112.
15. [15] Qian, X., Zhao, F.-Q., Collaborative interaction of Oct-2 with Oct-1 in transactivation of lactogenic hormones-induced β-casein gene expression in mammary epithelial cells. Gen. Comp. Endocrinol. 204 (Aug. 2014), 185–194.
16. [16] Klemm, J.D., Rould, M.A., aurora, R., Herr, W., pabo, C.O., Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell 77:1 (Apr. 1994), 21–32.
17. [17] Eaton, S., Calame, K., Multiple DNA sequence elements are necessary for the function of an immunoglobulin heavy chain promoter. Proc. Natl. Acad. Sci. U. S. A. 84:21 (Nov. 1987), 7634–7638.
18. [18] Hori, N., Nakano, H., Takeuchi, T., Kato, H., Hamaguchi, S., Oshimura, M., Sato, K., A Dyad Oct-binding Sequence Functions as a Maintenance Sequence for the Unmethylated State within theH19/Igf2-imprinted Control Region. J. Biol. Chem. 277:31 (Aug. 2002), 27960–27967.
19. [19] Wang, D., Yamamoto, S., Hijiya, N., Benveniste, E.N., Gladson, C.L., Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Oncogene, 19(50), Nov. 2000.
20. [20] Tomilin, A., Reményi, A., Lins, K., Bak, H., Leidel, S., Vriend, G., Wilmanns, M., Schöler, H.R., Synergism with the Coactivator OBF-1 (OCA-B, BOB-1) Is Mediated by a Specific POU Dimer Configuration. Cell 103:6 (Dec. 2000), 853–864.
21. [21] Reményi, A., Tomilin, A., Pohl, E., Lins, K., Philippsen, A., Reinbold, R., Schöler, H.R., Wilmanns, M., Differential dimer activities of the transcription factor Oct-1 by DNA-induced interface swapping. Mol. Cell 8:3 (Sep. 2001), 569–580.
22. [22] Kang, J., Gemberling, M., Nakamura, M., Whitby, F.G., Handa, H., Fairbrother, W.G., Tantin, D., A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress. Genes Dev. 23:2 (Jan. 2009), 208–222.
23. [23] Maddox, J., Shakya, A., South, S., Shelton, D., Andersen, J.N., Chidester, S., Kang, J., Gligorich, K.M., Jones, D.A., Spangrude, G.J., Welm, B.E., Tantin, D., Transcription factor Oct1 is a somatic and cancer stem cell determinant. PLoS Genet., 8(11), Nov. 2012, e1003048.
24. [24] Tantin, D., Gemberling, M., Callister, C., Fairbrother, W., High-throughput biochemical analysis of in vivo location data reveals novel distinct classes of POU5F1(Oct4)/DNA complexes. Genome Res. 18:4 (Apr. 2008), 631–639.
25. [25] Botquin, V., Hess, H., Fuhrmann, G., Anastassiadis, C., Gross, M.K., Vriend, G., Schöler, H.R., New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2. Genes Dev. 12:13 (Jul. 1998), 2073–2090.
26. [26] Ferraris, L., Stewart, A.P., Kang, J., DeSimone, A.M., Gemberling, M., Tantin, D., Fairbrother, W.G., Combinatorial binding of transcription factors in the pluripotency control regions of the genome. Genome Res. 21:7 (Jul. 2011), 1055–1064.
27. [27] Verrijzer, C.P., van Oosterhout, J.A., van der Vliet, P.C., The Oct-1 POU domain mediates interactions between Oct-1 and other POU proteins. Mol. Cell. Biol. 12:2 (Feb. 1992), 542–551.
28. [28] Bentrari, F., Chantôme, A., Knights, A., Jeannin, J.-F., Pance, A., Oct-2 forms a complex with Oct-1 on the iNOS promoter and represses transcription by interfering with recruitment of RNA PolII by Oct-1. Nucleic Acids Res. 43:20 (Nov. 2015), 9757–9765.
29. [29] Belsham, D.D., Mellon, P.L., Transcription factors Oct-1 and C/EBPβ (CCAAT/enhancer-binding protein-β) are involved in the glutamate/nitric oxide/cyclic-guanosine 5′-monophosphate-mediated repression of gonadotropin-releasing hormone gene expression. Mol. Endocrinol. 14:2 (Feb. 2000), 212–228.
30. [30] Hatada, E.N., Chen-Kiang, S., Scheidereit, C., Interaction and functional interference of C/EBPβ with octamer factors in immunoglobulin gene transcription. Eur. J. Immunol. 30:1 (Jan. 2000), 174–184.
31. [31] Ström, A.-C., Forsberg, M., Lillhager, P., Westin, G., The transcription factors Sp1 and Oct-1 interact physically to regulate human U2 snRNA gene expression. Nucleic Acids Res. 24:11 (Jun. 1996), 1981–1986.
32. [32] Qian, X., Zhao, F.-Q., Interactions of the ubiquitous octamer-binding transcription factor-1 with both the signal transducer and activator of transcription 5 and the glucocorticoid receptor mediate prolactin and glucocorticoid-induced β-casein gene expression in mammary epithelial cells. Int. J. Biochem. Cell Biol. 45:3 (Mar. 2013), 724–735.
33. [33] Magné, S., Caron, S., Charon, M., Rouyez, M.-C., Dusanter-Fourt, I., STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol. Cell. Biol. 23:24 (Dec. 2003), 8934–8945.
34. [34] Boulon, S., Dantonel, J.-C., Binet, V., Vié, A., Blanchard, J.-M., Hipskind, R.A., Philips, A., Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism. Mol. Cell. Biol. 22:22 (Nov. 2002), 7769–7779.
35. [35] Préfontaine, G.G., Walther, R., Giffin, W., Lemieux, M.E., Pope, L., Haché, R.J.G., Selective binding of steroid hormone receptors to octamer transcription factors determines transcriptional synergism at the mouse mammary tumor virus promoter. J. Biol. Chem. 274:38 (Sep. 1999), 26713–26719.
36. [36] Préfontaine, G.G., Lemieux, M.E., Giffin, W., Schild-Poulter, C., Pope, L., LaCasse, E., Walker, P., Haché, R.J.G., Recruitment of octamer transcription factors to DNA by glucocorticoid receptor. Mol. Cell. Biol. 18:6 (Jun. 1998), 3416–3430.
37. [37] Gonzalez, M.I., Robins, D.M., Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1. J. Biol. Chem. 276:9 (Mar. 2001), 6420–6428.
38. [38] Perri, A., Catalano, S., Bonofiglio, D., Vizza, D., Rovito, D., Qi, H., Aquila, S., Panza, S., Rizza, P., Lanzino, M., Andò, S., T3 enhances thyroid cancer cell proliferation through TRβ1/Oct-1-mediated cyclin D1 activation. Mol. Cell. Endocrinol. 382:1 (Jan. 2014), 205–217.
39. [39] Kakizawa, T., Miyamoto, T., Ichikawa, K., Kaneko, A., Suzuki, S., Hara, M., Nagasawa, T., Takeda, T., Mori, J., Kumagai, M., Hashizume, K., Functional interaction between Oct-1 and retinoid X receptor. J. Biol. Chem. 274:27 (Jul. 1999), 19103–19108.
40. [40] van Heel, D.A., Udalova, I.A., Silva, A.P.D., McGovern, D.P., Kinouchi, Y., Hull, J., Lench, N.J., Cardon, L.R., Carey, A.H., Jewell, D.P., Kwiatkowski, D., Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-κB transcription factors. Hum. Mol. Genet. 11:11 (May 2002), 1281–1289.
41. [41] Wang, V.E.H., Schmidt, T., Chen, J., Sharp, P.A., Tantin, D., Embryonic lethality, decreased erythropoiesis, and defective octamer-dependent promoter activation in oct-1-deficient mice. Mol. Cell. Biol. 24:3 (Feb. 2004), 1022–1032.
42. [42] Wang, V.E.H., Tantin, D., Chen, J., Sharp, P.A., B cell development and immunoglobulin transcription in oct-1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 101:7 (Feb. 2004), 2005–2010.
43. [43] Sebastiano, V., Dalvai, M., Gentile, L., Schubart, K., Sutter, J., Wu, G.-M., Tapia, N., Esch, D., Ju, J.-Y., Hübner, K., Bravo, M.J.A., Schöler, H.R., Cavaleri, F., Matthias, P., Oct1 regulates trophoblast development during early mouse embryogenesis. Development 137:21 (Nov. 2010), 3551–3560.
44. [44] Dalvai, M., Schubart, K., Besson, A., Matthias, P., Oct1 is required for mTOR-induced G1 cell cycle arrest via the control of p27(Kip1) expression. Cell Cycle 9:19 (Oct. 2010), 3933–3944.
45. [45] Shakya, A., Goren, A., Shalek, A., German, C.N., Snook, J., Kuchroo, V.K., Yosef, N., Chan, R.C., Regev, A., Williams, M.A., Tantin, D., Oct1 and OCA-B are selectively required for CD4 memory T cell function. J. Exp. Med., Oct. 2015 p. jem.20150363.
46. [46] Shakya, A., Cooksey, R., Cox, J.E., Wang, V., McClain, D.A., Tantin, D., Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity. Nat. Cell Biol. 11:3 (Mar. 2009), 320–327.
47. [47] Tantin, D., Schild-Poulter, C., Wang, V., Haché, R.J.G., Sharp, P.A., The octamer binding transcription factor oct-1 Is a stress sensor. Cancer Res. 65:23 (Dec. 2005), 10750–10758.
48. [48] Takahashi, S., Saito, S., Ohtani, N., Sakai, T., Involvement of the oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Res. 61:3 (Feb. 2001), 1187–1195.
49. [49] Jin, S., Fan, F., Fan, W., Zhao, H., Tong, T., Blanck, P., Alomo, I., Rajasekaran, B., Zhan, Q., Transcription factors oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. Oncogene 20:21 (May 2001), 2683–2690.
50. [50] Hirose, T., Sowa, Y., Takahashi, S., Saito, S., Yasuda, C., Shindo, N., Furuichi, K., Sakai, T., p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors oct-1 and NF-Y. Oncogene 22:49 (Oct. 2003), 7762–7773.
51. [51] Bellance, N., Pabst, L., Allen, G., Rossignol, R., Nagrath, D., Oncosecretomics coupled to bioenergetics identifies α-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: differential expression of c-myc, Oct1 and KLF4 coordinates metabolic changes. Biochim. Biophys. Acta 1817:11 (Nov. 2012), 2060–2071.
52. [52] Kang, J., Shen, Z., Lim, J.-M., Handa, H., Wells, L., Tantin, D., Regulation of Oct1/Pou2f1 transcription activity by O-GlcNAcylation. FASEB J. 27:7 (Jul. 2013), 2807–2817.
53. [53] Malhas, A.N., Lee, C.F., Vaux, D.J., Lamin B1 controls oxidative stress responses via oct-1. J. Cell Biol. 184:1 (Jan. 2009), 45–55.
54. [54] Kang, H.-B., Fan, J., Lin, R., Elf, S., Ji, Q., Zhao, L., Jin, L., Seo, J.H., Shan, C., Arbiser, J.L., Cohen, C., Brat, D., Miziorko, H.M., Kim, E., Abdel-Wahab, O., Merghoub, T., Fröhling, S., Scholl, C., Tamayo, P., Barbie, D.A., Zhou, L., Pollack, B.P., Fisher, K., Kudchadkar, R.R., Lawson, D.H., Sica, G., Rossi, M., Lonial, S., Khoury, H.J., Khuri, F.R., Lee, B.H., Boggon, T.J., He, C., Kang, S., Chen, J., Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling. Mol. Cell 59:3 (Aug. 2015), 345–358.
55. [55] Kang, J., Goodman, B., Zheng, Y., Tantin, D., Dynamic regulation of Oct1 during mitosis by phosphorylation and ubiquitination. PLoS ONE, 6(8), Aug. 2011, e23872.
56. [56] Ansari, K.I., Ogawa, D., Rooj, A.K., Lawler, S.E., Krichevsky, A.M., Johnson, M.D., Chiocca, E.A., Bronisz, A., Godlewski, J., Glucose-based regulation of miR-451/AMPK signaling depends on the OCT1 transcription factor. Cell Rep. 11:6 (May 2015), 902–909.
57. [57] Schild-Poulter, C., Shih, A., Tantin, D., Yarymowich, N.C., Soubeyrand, S., Sharp, P.A., Haché, R.J.G., DNA-PK phosphorylation sites on oct-1 promote cell survival following DNA damage. Oncogene 26:27 (Jan. 2007), 3980–3988.
58. [58] Van Hoof, D., Muñoz, J., Braam, S.R., Pinkse, M.W.H., Linding, R., Heck, A.J.R., Mummery, C.L., Krijgsveld, J., Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5:2 (Aug. 2009), 214–226.
59. [59] Reimand, J., Bader, G.D., Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol. Syst. Biol., 9, 2013, 637.
60. [60] Bertolino, E., Singh, H., POU/TBP cooperativity: a mechanism for enhancer action from a distance. Mol. Cell 10:2 (Aug. 2002), 397–407.
61. [61] Inamoto, S., Segil, N., Pan, Z.-Q., Kimura, M., Roeder, R.G., The cyclin-dependent kinase-activating kinase (CAK) assembly factor, MAT1, targets and enhances CAK Activity on the POU Domains of octamer transcription factors. J. Biol. Chem. 272:47 (Nov. 1997), 29852–29858.
62. [62] Reveneau, S., Petrakis, T.G., Goldring, C.E., Chantôme, A., Jeannin, J.-F., Pance, A., Oct-1 cooperates with the TATA binding initiation complex to control rapid transcription of human iNOS. Cell. Mol. Life Sci. 69:15 (Feb. 2012), 2609–2619.
63. [63] Shakya, A., Kang, J., Chumley, J., Williams, M.A., Tantin, D., Oct1 Is a switchable, bipotential stabilizer of repressed and inducible transcriptional states. J. Biol. Chem. 286:1 (Jan. 2011), 450–459.
64. [64] Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., Reinberg, D., Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13:15 (Aug. 1999), 1924–1935.
65. [65] Xue, Y., Wong, J., Moreno, G.T., Young, M.K., Côté, J., Wang, W., NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell 2:6 (Dec. 1998), 851–861.
66. [66] Tong, J.K., Hassig, C.A., Schnitzler, G.R., Kingston, R.E., Schreiber, S.L., Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 395:6705 (Oct. 1998), 917–921.
67. [67] Imai, S., Nishibayashi, S., Takao, K., Tomifuji, M., Fujino, T., Hasegawa, M., Takano, T., Dissociation of oct-1 from the nuclear peripheral structure induces the cellular aging-associated collagenase gene expression. Mol. Biol. Cell 8:12 (Dec. 1997), 2407–2419.
68. [68] Guelen, L., Pagie, L., Brasset, E., Meuleman, W., Faza, M.B., Talhout, W., Eussen, B.H., de Klein, A., Wessels, L., de Laat, W., van Steensel, B., Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature 453:7197 (Jun. 2008), 948–951.
69. [69] Wang, P., Jin, T., Hydrogen peroxide stimulates nuclear import of the POU homeodomain protein Oct-1 and its repressive effect on the expression of Cdx-2. BMC Cell Biol., 11(1), Jul. 2010, 56.
70. [70] Wang, P., Wang, Q., Sun, J., Wu, J., Li, H., Zhang, N., Huang, Y., Su, B., Li, R., Liu, L., Zhang, Y., Elsholtz, H.P., Hu, J., Gaisano, H.Y., Jin, T., POU homeodomain protein oct-1 functions as a sensor for cyclic AMP. J. Biol. Chem. 284:39 (Sep. 2009), 26456–26465.
71. [71] Kim, L.K., Esplugues, E., Zorca, C.E., Parisi, F., Kluger, Y., Kim, T.H., Galjart, N.J., Flavell, R.A., Oct-1 regulates IL-17 expression by directing interchromosomal associations in conjunction with CTCF in T Cells. Mol. Cell 54:1 (Apr. 2014), 56–66.
72. [72] García-Cosío, M., Santón, A., Martín, P., Camarasa, N., Montalbán, C., García, J.F., Bellas, C., Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma. Mod. Pathol. 17:12 (Jul. 2004), 1531–1538.
73. [73] Schreiber, E., Merchant, R.E., Wiestler, O.D., Fontana, A., Primary brain tumors differ in their expression of octamer deoxyribonucleic acid-binding transcription factors from long-term cultured glioma cell lines. Neurosurgery 34:1 (Jan. 1994), 129–135.
74. [74] Thomson, J.A., Parsons, P.G., Sturm, R.A., In vivo and in vitro expression of octamer binding proteins in human melanoma metastases, brain tissue, and fibroblasts. Pigment Cell Res. 6:1 (Feb. 1993), 13–22.
75. [75] DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D., Kramer, J.L., Alteri, R., Robbins, A.S., Jemal, A., Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 64:4 (Jul. 2014), 252–271.
76. [76] “Cancer statistics review, 1975–2012 - SEER statistics.” [Online]. Available: http://seer.cancer.gov/csr/1975_2012/. (Accessed: 23-Oct-2015).
77. [77] “Tumorscape.” [Online]. Available: http://www.broadinstitute.org/tumorscape/pages/portalHome.jsf. (Accessed: 04-Oct-2015).
78. [78] Qian, J., Kong, X., Deng, N., Tan, P., Chen, H., Wang, J., Li, Z., Hu, Y., Zou, W., Xu, J., Fang, J.-Y., OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer. Gut 64:1 (Jan. 2015), 37–48.
79. [79] Chen, X., Leung, S.Y., Yuen, S.T., Chu, K.-M., Ji, J., Li, R., Chan, A.S.Y., Law, S., Troyanskaya, O.G., Wong, J., So, S., Botstein, D., Brown, P.O., Variation in gene expression patterns in human gastric cancers. Mol. Biol. Cell 14:8 (Aug. 2003), 3208–3215.
80. [80] Wang, J., Yang, Y.-H., Wang, A.-Q., Yao, B., Xie, G., Feng, G., Zhang, Y., Cheng, Z.-S., Hui, L., Dai, T.-Z., Du, X.-B., Wang, D., Immunohistochemical detection of the raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Med. Oncol. 27:2 (Mar. 2009), 219–223.
81. [81] D'Errico, M., de Rinaldis, E., Blasi, M.F., Viti, V., Falchetti, M., Calcagnile, A., Sera, F., Saieva, C., Ottini, L., Palli, D., Palombo, F., Giuliani, A., Dogliotti, E., Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur. J. Cancer 45:3 (Feb. 2009), 461–469.
82. [82] Wang, Y., Song, G., Chen, J., Xiao, C., Li, C., Zhong, L., Sun, X., Wang, Z., Deng, G., Yu, F., Xue, Y., Tang, H., Peng, Z., Wang, X., Elevated OCT1 participates in colon tumorigenesis and independently predicts poor prognoses of colorectal cancer patients. Tumor Biol., Oct. 2015, 1–9.
83. [83] “Oncomine Main.” [Online]. Available: https://www.oncomine.org/resource/main.html#a%3A1830%3Bd%3A22218696%3Bdso%3AgeneOverex%3Bdt%3ApredefinedClass%3Bec%3A%5B2%5D%3Bepv%3A150001.151078%2C3508%3Bet%3Aover%3Bf%3A542580%3Bg%3A5451%3Bp%3A200001281%3Bpg%3A1%3Bpvf%3A2938%2C31927%2C150004%3Bscr%3Adatasets%3Bss%3Aanalysis%3Bth%3Ag100.0%2Cp1.000%2Cfc0.0%3Bv%3A18. (Accessed: 15-Oct-2015).
84. [84] Lee, J.-S., Leem, S.-H., Lee, S.-Y., Kim, S.-C., Park, E.-S., Kim, S.-B., Kim, S.-K., Kim, Y.-J., Kim, W.-J., Chu, I.-S., Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 28:16 (Jun. 2010), 2660–2667.
85. [85] Sanchez-Carbayo, M., Socci, N.D., Lozano, J., Saint, F., Cordon-Cardo, C., Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24:5 (Feb. 2006), 778–789.
86. [86] Dyrskjøt, L., Kruhøffer, M., Thykjaer, T., Marcussen, N., Jensen, J.L., Møller, K., Ørntoft, T.F., Gene expression in the urinary bladder A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64:11 (Jun. 2004), 4040–4048.
87. [87] Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., Hallett, M., Park, M., Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14:5 (May 2008), 518–527.
88. [88] Zhao, H., Langerød, A., Ji, Y., Nowels, K.W., Nesland, J.M., Tibshirani, R., Bukholm, I.K., Kåresen, R., Botstein, D., Børresen-Dale, A.-L., Jeffrey, S.S., Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell 15:6 (Jun. 2004), 2523–2536.
89. [89] Curtis, C., Shah, S.P., Chin, S.-F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., Gräf, S., Ha, G., Haffari, G., Bashashati, A., Russell, R., McKinney, S., Metabric Group, Langerød, A., Green, A., Provenzano, E., Wishart, G., Pinder, S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, A., Børresen-Dale, A.-L., Brenton, J.D., Tavaré, S., Caldas, C., Aparicio, S., The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:7403 (Jun. 2012), 346–352.
90. [90] Xiao, S., Liao, S., Zhou, Y., Jiang, B., Li, Y., Xue, M., High expression of octamer transcription factor 1 in cervical cancer. Oncol. Lett. 7:6 (Jun. 2014), 1889–1894.
91. [91] Sharpe, D.J., Orr, K.S., Moran, M., White, S.J., McQuaid, S., Lappin, T.R., Thompson, A., James, J.A., POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer. Oncotarget 5:18 (Sep. 2014), 8803–8815.
92. [92] Xu, S.-H., Huang, J.-Z., Xu, M.-L., Yu, G., Yin, X.-F., Chen, D., Yan, G.-R., ACK1 promotes gastric cancer epithelial–mesenchymal transition and metastasis through AKT–POU2F1–ECD signalling. J. Pathol. 236:2 (Jun. 2015), 175–185.
93. [93] Hwang-Verslues, W.W., Chang, P.-H., Jeng, Y.-M., Kuo, W.-H., Chiang, P.-H., Chang, Y.-C., Hsieh, T.-H., Su, F.-Y., Lin, L.-C., Abbondante, S., Yang, C.-Y., Hsu, H.-M., Yu, J.-C., Chang, K.-J., Shew, J.-Y., Lee, E.Y.-H.P., Lee, W.-H., Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc. Natl. Acad. Sci. 110:30 (Jul. 2013), 12331–12336.
94. [94] Almeida, R., Almeida, J., Shoshkes, M., Mendes, N., Mesquita, P., Silva, E., Van Seuningen, I., Reis, C.A., Santos-Silva, F., David, L., OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J. Pathol. 207:4 (Dec. 2005), 396–401.
95. [95] Jeong, S.-H., Lee, Y.-J., Cho, B.-I., Ha, W.-S., Choi, S.-K., Jung, E.-J., Ju, Y.-T., Jeong, C.-Y., Ko, G.H., Yoo, J., Hong, S.-C., OCT-1 overexpression is associated with poor prognosis in patients with well-differentiated gastric cancer. Tumor Biol. 35:6 (Feb. 2014), 5501–5509.
96. [96] Hernández, P., Solé, X., Valls, J., Moreno, V., Capellá, G., Urruticoechea, A., Pujana, M.A., Integrative analysis of a cancer somatic mutome. Mol. Cancer, 6(1), Feb. 2007, 13.
97. [97] Li, Y., Dong, M., Kong, F., Zhou, J., Octamer transcription factor 1 mediates epithelial-mesenchymal transition in colorectal cancer. Tumor Biol., Jul. 2015, 1–6.
98. [98] Obinata, D., Takayama, K., Urano, T., Murata, T., Kumagai, J., Fujimura, T., Ikeda, K., Horie-Inoue, K., Homma, Y., Ouchi, Y., Takahashi, S., Inoue, S., Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int. J. Cancer 130:5 (Mar. 2012), 1021–1028.
99. [99] Kalamohan, K., Periasamy, J., Bhaskar Rao, D., Barnabas, G.D., Ponnaiyan, S., Ganesan, K., Transcriptional coexpression network reveals the involvement of varying stem cell features with different dysregulations in different gastric cancer subtypes. Mol. Oncol. 8:7 (Oct. 2014), 1306–1325.
100. [100] Reymann, S., Borlak, J., Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network. BMC Syst. Biol., 2(1), May 2008, 46.
101. [101] Ben-Porath, I., Thomson, M.W., Carey, V.J., Ge, R., Bell, G.W., Regev, A., Weinberg, R.A., An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40:5 (May 2008), 499–507.
102. [102] Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W.C., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., Futreal, P.A., Mutations of the BRAF gene in human cancer. Nature 417:6892 (Jun. 2002), 949–954.
103. [103] Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., Kok, C.Y., Jia, M., De, T., Teague, J.W., Stratton, M.R., McDermott, U., Campbell, P.J., COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43:Database issue (Jan. 2015), D805–D811.
104. [104] Brockman, J.L., Schuler, L.A., Prolactin signals via Stat5 and oct-1 to the proximal cyclin D1 promoter. Mol. Cell. Endocrinol. 239:1–2 (Jul. 2005), 45–53.
105. [105] Tang, H.-R., Luo, X.-Q., Xu, G., Wang, Y., Feng, Z.-J., Xu, H., Shi, Y.-W., Zhang, Q., Wu, L.-G., Xue, C.-Q., Wang, C.-W., Wu, C.-Y., High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma. World J. Gastroenterol. 18:48 (Dec. 2012), 7319–7326.
106. [106] Hoffman, B., Liebermann, D.A., Gadd45 in modulation of solid tumors and leukemia. Liebermann, D.A., Hoffman, B., (eds.) Gadd45 Stress Sensor Genes, 2013, Springer, New York, 21–33.
107. [107] Salvador, J.M., Brown-Clay, J.D., Jr, A.J.F., Gadd45 in stress signaling, cell cycle control, and apoptosis. Liebermann, D.A., Hoffman, B., (eds.) Gadd45 Stress Sensor Genes, 2013, Springer, New York, 1–19.
108. [108] Mancini, M., Leo, E., Aluigi, M., Marcozzi, C., Borsi, E., Barbieri, E., Santucci, M.A., Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in bcr-abl-expressing cells is driven by oct-1 transcription factor. Leuk. Res. 36:8 (Aug. 2012), 1028–1034.
109. [109] Fan, W., Jin, S., Tong, T., Zhao, H., Fan, F., Antinore, M.J., Rajasekaran, B., Wu, M., Zhan, Q., BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J. Biol. Chem. 277:10 (Mar. 2002), 8061–8067.
110. [110] Harte, M.T., O'Brien, G.J., Ryan, N.M., Gorski, J.J., Savage, K.I., Crawford, N.T., Mullan, P.B., Harkin, D.P., BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res. 70:6 (Mar. 2010), 2538–2547.
111. [111] Bhar, A., Haubrock, M., Mukhopadhyay, A., Maulik, U., Bandyopadhyay, S., Wingender, E., Coexpression and coregulation analysis of time-series gene expression data in estrogen-induced breast cancer cell. Algorithms Mol. Biol., 8, 2013, 9.
112. [112] Hosey, A.M., Gorski, J.J., Murray, M.M., Quinn, J.E., Chung, W.Y., Stewart, G.E., James, C.R., Farragher, S.M., Mulligan, J.M., Scott, A.N., Dervan, P.A., Johnston, P.G., Couch, F.J., Daly, P.A., Kay, E., McCann, A., Mullan, P.B., Harkin, D.P., Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J. Natl. Cancer Inst. 99:22 (Nov. 2007), 1683–1694.
113. [113] Wang, R.-H., Yu, H., Deng, C.-X., A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc. Natl. Acad. Sci. U. S. A. 101:49 (Dec. 2004), 17108–17113.
114. [114] Saha, T., Rih, J.K., Roy, R., Ballal, R., Rosen, E.M., Transcriptional regulation of the base excision repair pathway by BRCA1. J. Biol. Chem. 285:25 (Jun. 2010), 19092–19105.
115. [115] Luo, X., Huang, Y., Sheikh, M.S., Cloning and characterization of a novel gene PDRG that is differentially regulated by p53 and ultraviolet radiation. Oncogene 22:46 (2003), 7247–7257.
116. [116] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:2 (Feb. 2011), 85–95.
117. [117] Bonnet, S., Archer, S.L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., Lee, C.T., Lopaschuk, G.D., Puttagunta, L., Bonnet, S., Harry, G., Hashimoto, K., Porter, C.J., Andrade, M.A., Thebaud, B., Michelakis, E.D., A mitochondria-K + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:1 (Jan. 2007), 37–51.
118. [118] Muñoz, J., Stange, D.E., Schepers, A.G., van de Wetering, M., Koo, B.-K., Itzkovitz, S., Volckmann, R., Kung, K.S., Koster, J., Radulescu, S., Myant, K., Versteeg, R., Sansom, O.J., van Es, J.H., Barker, N., van Oudenaarden, A., Mohammed, S., Heck, A.J.R., Clevers, H., The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent ‘+ 4′ cell markers. EMBO J. 31:14 (Jul. 2012), 3079–3091.
119. [119] Bane, A., Viloria-Petit, A., Pinnaduwage, D., Mulligan, A.M., O'Malley, F.P., Andrulis, I.L., Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Res. Treat. 140:1 (Jul. 2013), 195–205.
120. [120] Diehn, M., Cho, R.W., Lobo, N.A., Kalisky, T., Dorie, M.J., Kulp, A.N., Qian, D., Lam, J.S., Ailles, L.E., Wong, M., Joshua, B., Kaplan, M.J., Wapnir, I., Dirbas, F.M., Somlo, G., Garberoglio, C., Paz, B., Shen, J., Lau, S.K., Quake, S.R., Brown, J.M., Weissman, I.L., Clarke, M.F., Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:7239 (Apr. 2009), 780–783.
121. [121] Phillips, T.M., McBride, W.H., Pajonk, F., The response of CD24(−/low)/CD44 + breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98:24 (Dec. 2006), 1777–1785.
122. [122] Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D., Rich, J.N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:7120 (Dec. 2006), 756–760.
123. [123] Durmus, S., Hendrikx, J.J.M.A., Schinkel, A.H., Chapter one — apical ABC transporters and cancer chemotherapeutic drug disposition. Schuetz, J.D., Ishikawa, T., (eds.) Advances in Cancer Research, vol. 125, 2015, Academic Press, 1–41.
124. [124] Charafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti, P., Hur, M.-H., Diebel, M.E., Monville, F., Dutcher, J., Brown, M., Viens, P., Xerri, L., Bertucci, F., Stassi, G., Dontu, G., Birnbaum, D., Wicha, M.S., Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69:4 (Feb. 2009), 1302–1313.
125. [125] Gupta, G.P., Perk, J., Acharyya, S., de Candia, P., Mittal, V., Todorova-Manova, K., Gerald, W.L., Brogi, E., Benezra, R., Massagué, J., ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc. Natl. Acad. Sci. U. S. A. 104:49 (Dec. 2007), 19506–19511.
126. [126] Li, F., Tiede, B., Massagué, J., Kang, Y., Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 17:1 (Jan. 2007), 3–14.
127. [127] Rodrigues, L.R., Teixeira, J.A., Schmitt, F.L., Paulsson, M., Lindmark-Mänsson, H., The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol. Biomark. Prev. 16:6 (Jun. 2007), 1087–1097.
128. [128] Tuck, A.B., Elliott, B.E., Hota, C., Tremblay, E., Chambers, A.F., Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (met). J. Cell. Biochem. 78:3 (Sep. 2000), 465–475.
129. [129] Pfeuffer, I., Klein-Hessling, S., Heinfling, A., Chuvpilo, S., Escher, C., Brabletz, T., Hentsch, B., Schwarzenbach, H., Matthias, P., Serfling, E., Octamer factors exert a dual effect on the IL-2 and IL-4 promoters. J. Immunol. 153:12 (Dec. 1994), 5572–5585.
130. [130] Cron, R.Q., Zhou, B., Brunvand, M.W., Lewis, D.B., Octamer proteins inhibit IL-4 gene transcription in normal human CD4 T cells. Genes Immun. 2:8 (Dec. 2001), 464–468.
131. [131] Kaushansky, K., Shoemaker, S.G., O'Rork, C.A., McCarty, J.M., Coordinate regulation of multiple human lymphokine genes by oct-1 and potentially novel 45 and 43 kDa polypeptides. J. Immunol. 152:4 (Feb. 1994), 1812–1820.
132. [132] Voleti, B., Agrawal, A., Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-κB on the proximal promoter. J. Immunol. 175:5 (Sep. 2005), 3386–3390.
133. [133] Kim, Y.-M., Ko, C.-B., Park, Y.-P., Kim, Y.J., Paik, S.-G., Octamer motif and downstream NF-κB-mediated induction of the inducible nitric oxide synthase Gene Expression in RAW 264.7 macrophages. Mol. Cell 9:1 (Feb. 1999), 99–109.
134. [134] Fujimori, K., Kanaoka, Y., Sakaguchi, Y., Urade, Y., Transcriptional activation of the human hematopoietic prostaglandin D Synthase Gene in megakaryoblastic cells ROLES OF THE oct-1 ELEMENT IN THE 5′-FLANKING REGION AND THE AP-2 ELEMENT IN THE UNTRANSLATED EXON 1. J. Biol. Chem. 275:51 (Dec. 2000), 40511–40516.
135. [135] Liu, Y., Wang, Y., Sun, X., Mei, C., Wang, L., Li, Z., Zha, X., miR-449a promotes liver cancer cell apoptosis by down-regulation of calpain6 and POU2F1. Oncotarget, Aug. 2015.
136. [136] Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H., Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J., Shafer, A., Neri, F., Lee, K., Kutyavin, T., Stehling-Sun, S., Johnson, A.K., Canfield, T.K., Giste, E., Diegel, M., Bates, D., Hansen, R.S., Neph, S., Sabo, P.J., Heimfeld, S., Raubitschek, A., Ziegler, S., Cotsapas, C., Sotoodehnia, N., Glass, I., Sunyaev, S.R., Kaul, R., Stamatoyannopoulos, J.A., Systematic localization of common disease-associated variation in regulatory DNA. Science 337:6099 (Sep. 2012), 1190–1195.
137. [137] Pankratova, E.V., Deyev, I.E., Zhenilo, S.V., Polanovsky, O.L., Tissue-specific isoforms of the ubiquitous transcription factor oct-1. Mol. Gen. Genomics. 266:2 (Oct. 2001), 239–245.
138. [138] Daub, H., Olsen, J.V., Bairlein, M., Gnad, F., Oppermann, F.S., Körner, R., Greff, Z., Kéri, G., Stemmann, O., Mann, M., Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol. Cell 31:3 (Aug. 2008), 438–448.
139. [139] Dephoure, N., Zhou, C., Villén, J., Beausoleil, S.A., Bakalarski, C.E., Elledge, S.J., Gygi, S.P., A quantitative atlas of mitotic phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 105:31 (Aug. 2008), 10762–10767.
140. [140] Segil, N., Roberts, S.B., Heintz, N., Mitotic phosphorylation of the oct-1 homeodomain and regulation of oct-1 DNA binding activity. Science 254:5039 (Dec. 1991), 1814–1816.